TY - JOUR AU - Moreaux, J. AU - Klein, B. AU - Bataille, R. AU - Descamps, G. AU - Maïga, S. AU - Hose, D. PY - 2011 DA - 2011// TI - A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines JO - Haematologica VL - 96 UR - https://doi.org/10.3324/haematol.2010.033456 DO - 10.3324/haematol.2010.033456 ID - Moreaux2011 ER - TY - JOUR AU - Manier, S. AU - Salem, K. Z. AU - Park, J. AU - Landau, D. A. AU - Getz, G. AU - Ghobrial, I. M. PY - 2017 DA - 2017// TI - Genomic complexity of multiple myeloma and its clinical implications JO - Nat Rev Clin Oncol VL - 14 UR - https://doi.org/10.1038/nrclinonc.2016.122 DO - 10.1038/nrclinonc.2016.122 ID - Manier2017 ER - TY - JOUR AU - Sonneveld, P. AU - Avet-Loiseau, H. AU - Lonial, S. AU - Usmani, S. AU - Siegel, D. AU - Anderson, K. C. PY - 2016 DA - 2016// TI - Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-01-631200 DO - 10.1182/blood-2016-01-631200 ID - Sonneveld2016 ER - TY - JOUR AU - Moreau, P. AU - Cavo, M. AU - Sonneveld, P. AU - Rosinol, L. AU - Attal, M. AU - Pezzi, A. PY - 2014 DA - 2014// TI - Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0329 DO - 10.1200/JCO.2013.53.0329 ID - Moreau2014 ER - TY - JOUR AU - Sonneveld, P. AU - Wit, E. AU - Moreau, P. PY - 2017 DA - 2017// TI - How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? JO - Crit Rev Oncol Hematol VL - 112 UR - https://doi.org/10.1016/j.critrevonc.2017.02.007 DO - 10.1016/j.critrevonc.2017.02.007 ID - Sonneveld2017 ER - TY - JOUR AU - Tessoulin, B. AU - Descamps, G. AU - Moreau, P. AU - Maïga, S. AU - Lodé, L. AU - Godon, C. PY - 2014 DA - 2014// TI - PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548800 DO - 10.1182/blood-2014-01-548800 ID - Tessoulin2014 ER - TY - JOUR AU - Maïga, S. AU - Brosseau, C. AU - Descamps, G. AU - Dousset, C. AU - Gomez-Bougie, P. AU - Chiron, D. PY - 2015 DA - 2015// TI - A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines JO - Cytometry A VL - 87 UR - https://doi.org/10.1002/cyto.a.22643 DO - 10.1002/cyto.a.22643 ID - Maïga2015 ER - TY - JOUR AU - Zhan, F. AU - Huang, Y. AU - Colla, S. AU - Stewart, J. P. AU - Hanamura, I. AU - Gupta, S. PY - 2006 DA - 2006// TI - The molecular classification of multiple myeloma JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2005-11-013458 DO - 10.1182/blood-2005-11-013458 ID - Zhan2006 ER - TY - JOUR AU - Surget, S. AU - Chiron, D. AU - Gomez-Bougie, P. AU - Descamps, G. AU - Ménoret, E. AU - Bataille, R. PY - 2012 DA - 2012// TI - Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-0487 DO - 10.1158/0008-5472.CAN-12-0487 ID - Surget2012 ER - TY - JOUR AU - Bodet, L. AU - Gomez-Bougie, P. AU - Touzeau, C. AU - Dousset, C. AU - Descamps, G. AU - Maïga, S. PY - 2011 DA - 2011// TI - ABT-737 is highly effective against molecular subgroups of multiple myeloma JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2010-11-317438 DO - 10.1182/blood-2010-11-317438 ID - Bodet2011 ER - TY - JOUR AU - Touzeau, C. AU - Dousset, C. AU - Gouill, S. AU - Sampath, D. AU - Leverson, J. D. AU - Souers, A. J. PY - 2014 DA - 2014// TI - The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.216 DO - 10.1038/leu.2013.216 ID - Touzeau2014 ER - TY - JOUR AU - Surget, S. AU - Lemieux-Blanchard, E. AU - Maïga, S. AU - Descamps, G. AU - Gouill, S. AU - Moreau, P. PY - 2014 DA - 2014// TI - Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other JO - Leuk Lymphoma VL - 55 UR - https://doi.org/10.3109/10428194.2013.871277 DO - 10.3109/10428194.2013.871277 ID - Surget2014 ER - TY - JOUR AU - Surget, S. AU - Descamps, G. AU - Brosseau, C. AU - Normant, V. AU - Maïga, S. AU - Gomez-Bougie, P. PY - 2014 DA - 2014// TI - RITA (reactivating p53 and inducing tumor apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-437 DO - 10.1186/1471-2407-14-437 ID - Surget2014 ER - TY - JOUR AU - Kervoëlen, C. AU - Ménoret, E. AU - Gomez-Bougie, P. AU - Bataille, R. AU - Godon, C. AU - Marionneau-Lambot, S. PY - 2015 DA - 2015// TI - Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4616 DO - 10.18632/oncotarget.4616 ID - Kervoëlen2015 ER - TY - JOUR AU - Gerstung, M. AU - Pellagatti, A. AU - Malcovati, L. AU - Giagounidis, A. AU - Porta, M. G. D. AU - Jädersten, M. PY - 2015 DA - 2015// TI - Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms6901 DO - 10.1038/ncomms6901 ID - Gerstung2015 ER - TY - JOUR AU - Yu, G. AU - He, Q. -. Y. PY - 2016 DA - 2016// TI - ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization JO - Mol Biosyst VL - 12 UR - https://doi.org/10.1039/C5MB00663E DO - 10.1039/C5MB00663E ID - Yu2016 ER - TY - JOUR AU - Yu, G. AU - Wang, L. -. G. AU - Han, Y. AU - He, Q. -. Y. PY - 2012 DA - 2012// TI - clusterProfiler: an R package for comparing biological themes among gene clusters JO - OMICS VL - 16 UR - https://doi.org/10.1089/omi.2011.0118 DO - 10.1089/omi.2011.0118 ID - Yu2012 ER - TY - STD TI - Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56. https://doi.org/10.1101/gr.239244.118 ID - ref18 ER - TY - JOUR AU - Zheng, X. AU - Levine, D. AU - Shen, J. AU - Gogarten, S. M. AU - Laurie, C. AU - Weir, B. S. PY - 2012 DA - 2012// TI - A high-performance computing toolset for relatedness and principal component analysis of SNP data JO - Bioinformatics VL - 28 UR - https://doi.org/10.1093/bioinformatics/bts606 DO - 10.1093/bioinformatics/bts606 ID - Zheng2012 ER - TY - JOUR AU - Walker, B. A. AU - Boyle, E. M. AU - Wardell, C. P. AU - Murison, A. AU - Begum, D. B. AU - Dahir, N. M. PY - 2015 DA - 2015// TI - Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.1503 DO - 10.1200/JCO.2014.59.1503 ID - Walker2015 ER - TY - JOUR AU - Chapman, M. A. AU - Lawrence, M. S. AU - Keats, J. J. AU - Cibulskis, K. AU - Sougnez, C. AU - Schinzel, A. C. PY - 2011 DA - 2011// TI - Initial genome sequencing and analysis of multiple myeloma JO - Nature VL - 471 UR - https://doi.org/10.1038/nature09837 DO - 10.1038/nature09837 ID - Chapman2011 ER - TY - JOUR AU - Lohr, J. G. AU - Stojanov, P. AU - Carter, S. L. AU - Cruz-Gordillo, P. AU - Lawrence, M. S. AU - Auclair, D. PY - 2014 DA - 2014// TI - Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2013.12.015 DO - 10.1016/j.ccr.2013.12.015 ID - Lohr2014 ER - TY - JOUR AU - Chavan, S. S. AU - He, J. AU - Tytarenko, R. AU - Deshpande, S. AU - Patel, P. AU - Bailey, M. PY - 2017 DA - 2017// TI - Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker JO - Blood Cancer J VL - 7 UR - https://doi.org/10.1038/bcj.2017.12 DO - 10.1038/bcj.2017.12 ID - Chavan2017 ER - TY - JOUR AU - Weinhold, N. AU - Ashby, C. AU - Rasche, L. AU - Chavan, S. S. AU - Stein, C. AU - Stephens, O. W. PY - 2016 DA - 2016// TI - Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2016-06-723007 DO - 10.1182/blood-2016-06-723007 ID - Weinhold2016 ER - TY - JOUR AU - Barbieri, M. AU - Manzoni, M. AU - Fabris, S. AU - Ciceri, G. AU - Todoerti, K. AU - Simeon, V. PY - 2016 DA - 2016// TI - Compendium of FAM46C gene mutations in plasma cell dyscrasias JO - Br J Haematol VL - 174 UR - https://doi.org/10.1111/bjh.13793 DO - 10.1111/bjh.13793 ID - Barbieri2016 ER - TY - JOUR AU - Cifola, I. AU - Lionetti, M. AU - Pinatel, E. AU - Todoerti, K. AU - Mangano, E. AU - Pietrelli, A. PY - 2015 DA - 2015// TI - Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4028 DO - 10.18632/oncotarget.4028 ID - Cifola2015 ER - TY - JOUR AU - Lionetti, M. AU - Barbieri, M. AU - Todoerti, K. AU - Agnelli, L. AU - Marzorati, S. AU - Fabris, S. PY - 2015 DA - 2015// TI - Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4434 DO - 10.18632/oncotarget.4434 ID - Lionetti2015 ER - TY - JOUR AU - Lionetti, M. AU - Barbieri, M. AU - Manzoni, M. AU - Fabris, S. AU - Bandini, C. AU - Todoerti, K. PY - 2016 DA - 2016// TI - Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7241 DO - 10.18632/oncotarget.7241 ID - Lionetti2016 ER - TY - JOUR AU - Jurczyszyn, A. AU - Castillo, J. J. AU - Avivi, I. AU - Czepiel, J. AU - Davila, J. AU - Vij, R. PY - 2018 DA - 2018// TI - Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients JO - Leuk Lymphoma VL - 0 ID - Jurczyszyn2018 ER - TY - JOUR AU - Lagana, A. AU - Melnekoff, D. AU - Beno, I. AU - Leshchenko, V. AU - Perumal, D. AU - Keats, J. J. PY - 2017 DA - 2017// TI - Clonal evolution in newly diagnosed multiple myeloma patients: a follow-up study from the Mmrf Commpass Genomics Project JO - Blood VL - 130 ID - Lagana2017 ER - TY - JOUR AU - Lehners, N. AU - Toprak, U. H. AU - Xu, J. AU - Paramasivam, N. AU - Hübschmann, D. AU - Fröhlich, M. PY - 2017 DA - 2017// TI - Comprehensive genomic characterization of refractory multiple myeloma reveals a complex mutational and structural landscape associated with drug resistance JO - Blood VL - 130 ID - Lehners2017 ER - TY - JOUR AU - Pawlyn, C. AU - Kaiser, M. F. AU - Heuck, C. AU - Melchor, L. AU - Wardell, C. P. AU - Murison, A. PY - 2016 DA - 2016// TI - The spectrum and clinical impact of epigenetic modifier mutations in myeloma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1790 DO - 10.1158/1078-0432.CCR-15-1790 ID - Pawlyn2016 ER - TY - STD TI - Tessoulin B, Eveillard M, Lok A, Chiron D, Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S, Pellat-Deceunynck C. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Rev. 2017;31(4):251–59. https://doi.org/10.1016/j.blre.2017.03.001 ID - ref33 ER - TY - JOUR AU - Tao, Z. -. F. AU - Hasvold, L. AU - Wang, L. AU - Wang, X. AU - Petros, A. M. AU - Park, C. H. PY - 2014 DA - 2014// TI - Discovery of a potent and selective BCL-XL inhibitor with in vivo activity JO - ACS Med Chem Lett VL - 5 UR - https://doi.org/10.1021/ml5001867 DO - 10.1021/ml5001867 ID - Tao2014 ER - TY - JOUR AU - Leverson, J. D. AU - Zhang, H. AU - Chen, J. AU - Tahir, S. K. AU - Phillips, D. C. AU - Xue, J. PY - 2015 DA - 2015// TI - Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) JO - Cell Death Dis VL - 6 UR - https://doi.org/10.1038/cddis.2014.561 DO - 10.1038/cddis.2014.561 ID - Leverson2015 ER - TY - JOUR AU - Finn, R. S. AU - Dering, J. AU - Conklin, D. AU - Kalous, O. AU - Cohen, D. J. AU - Desai, A. J. PY - 2009 DA - 2009// TI - PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro JO - Breast Cancer Res VL - 11 UR - https://doi.org/10.1186/bcr2419 DO - 10.1186/bcr2419 ID - Finn2009 ER - TY - JOUR AU - Annunziata, C. M. AU - Davis, R. E. AU - Demchenko, Y. AU - Bellamy, W. AU - Gabrea, A. AU - Zhan, F. PY - 2007 DA - 2007// TI - Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma JO - Cancer Cell VL - 12 UR - https://doi.org/10.1016/j.ccr.2007.07.004 DO - 10.1016/j.ccr.2007.07.004 ID - Annunziata2007 ER - TY - JOUR AU - Nieves-Neira, W. AU - Rivera, M. I. AU - Kohlhagen, G. AU - Hursey, M. L. AU - Pourquier, P. AU - Sausville, E. A. PY - 1999 DA - 1999// TI - DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells JO - Mol Pharmacol VL - 56 UR - https://doi.org/10.1124/mol.56.3.478 DO - 10.1124/mol.56.3.478 ID - Nieves-Neira1999 ER - TY - JOUR AU - Lee, H. C. AU - Wang, H. AU - Baladandayuthapani, V. AU - Lin, H. AU - He, J. AU - Jones, R. J. PY - 2017 DA - 2017// TI - RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma JO - Br J Haematol VL - 177 UR - https://doi.org/10.1111/bjh.14525 DO - 10.1111/bjh.14525 ID - Lee2017 ER - TY - JOUR AU - Bolli, N. AU - Li, Y. AU - Sathiaseelan, V. AU - Raine, K. AU - Jones, D. AU - Ganly, P. PY - 2016 DA - 2016// TI - A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma JO - Blood Cancer J VL - 6 UR - https://doi.org/10.1038/bcj.2016.72 DO - 10.1038/bcj.2016.72 ID - Bolli2016 ER - TY - JOUR AU - Drexler, H. G. AU - Dirks, W. G. AU - MacLeod, R. A. PY - 1999 DA - 1999// TI - False human hematopoietic cell lines: cross-contaminations and misinterpretations JO - Leukemia VL - 13 UR - https://doi.org/10.1038/sj.leu.2401510 DO - 10.1038/sj.leu.2401510 ID - Drexler1999 ER - TY - STD TI - Drexler HG, Dirks WG, MacLeod RA, Uphoff CC. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal. Int J Cancer. 2017;140(5):1209–214. ID - ref42 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Klein, M. E. AU - Kovatcheva, M. AU - Davis, L. E. AU - Tap, W. D. AU - Koff, A. PY - 2018 DA - 2018// TI - CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought JO - Cancer Cell VL - 34 UR - https://doi.org/10.1016/j.ccell.2018.03.023 DO - 10.1016/j.ccell.2018.03.023 ID - Klein2018 ER - TY - JOUR AU - Niesvizky, R. AU - Badros, A. Z. AU - Costa, L. J. AU - Ely, S. A. AU - Singhal, S. B. AU - Stadtmauer, E. A. PY - 2015 DA - 2015// TI - Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma JO - Leuk Lymphoma VL - 56 UR - https://doi.org/10.3109/10428194.2015.1030641 DO - 10.3109/10428194.2015.1030641 ID - Niesvizky2015 ER - TY - JOUR AU - Leonard, J. P. AU - LaCasce, A. S. AU - Smith, M. R. AU - Noy, A. AU - Chirieac, L. R. AU - Rodig, S. J. PY - 2012 DA - 2012// TI - Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-388298 DO - 10.1182/blood-2011-10-388298 ID - Leonard2012 ER - TY - JOUR AU - Kwapisz, D. PY - 2018 DA - 2018// TI - Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies JO - Breast Cancer VL - 25 UR - https://doi.org/10.1007/s12282-018-0864-6 DO - 10.1007/s12282-018-0864-6 ID - Kwapisz2018 ER - TY - STD TI - Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau J-F, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C. p53 regulates CD46 expression and Measles virus infection in myeloma cells. Blood Advances. In press. ID - ref48 ER - TY - JOUR AU - Mroczek, S. AU - Chlebowska, J. AU - Kuliński, T. M. AU - Gewartowska, O. AU - Gruchota, J. AU - Cysewski, D. PY - 2017 DA - 2017// TI - The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-00578-5 DO - 10.1038/s41467-017-00578-5 ID - Mroczek2017 ER - TY - JOUR AU - Schoggins, J. W. AU - Wilson, S. J. AU - Panis, M. AU - Murphy, M. Y. AU - Jones, C. T. AU - Bieniasz, P. PY - 2011 DA - 2011// TI - A diverse range of gene products are effectors of the type I interferon antiviral response JO - Nature VL - 472 UR - https://doi.org/10.1038/nature09907 DO - 10.1038/nature09907 ID - Schoggins2011 ER - TY - JOUR AU - Dispenzieri, A. AU - Tong, C. AU - LaPlant, B. AU - Lacy, M. Q. AU - Laumann, K. AU - Dingli, D. PY - 2017 DA - 2017// TI - Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2017.120 DO - 10.1038/leu.2017.120 ID - Dispenzieri2017 ER - TY - JOUR AU - Christofferson, A. AU - Nasser, S. AU - Aldrich, J. AU - Penaherrera, D. AU - Legendre, C. AU - Benard, B. PY - 2017 DA - 2017// TI - Integrative analysis of the genomic landscape underlying multiple myeloma at diagnosis: an Mmrf Commpass Analysis JO - Blood VL - 130 ID - Christofferson2017 ER - TY - JOUR AU - Kotschy, A. AU - Szlavik, Z. AU - Murray, J. AU - Davidson, J. AU - Maragno, A. L. AU - Toumelin-Braizat, G. PY - 2016 DA - 2016// TI - The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models JO - Nature VL - 538 UR - https://doi.org/10.1038/nature19830 DO - 10.1038/nature19830 ID - Kotschy2016 ER -